Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma. Primary Objective * To assess if the flow-cytometry assessed MRD-negative remission rate following an immunotherapy-based Induction in NCI-high risk patients without favorable genetic features is higher than the results of similar patients treated on AALL1131. Secondary Objectives * To compare flow-cytometry assessed MRD-negative rates at the end of Induction for patients treated with this therapy compared to similar patients treated on TOT17. * To compare the rate of significant toxicities in patients treated with this therapy to those treated with standard-risk therapy on TOT17. * To assess the event free and overall survival of patients treated with this therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 do 18,99 lat w momencie włączenia do badania
- •Rozpoznana białaczka limfoblastyczna lub chłoniak limfoblastyczny typu B-komórkowego
- •Brak wcześniejszej chemioterapii (oprócz leczenia dozwolonego w ramach innego badania INITIALL)
- •Należenie do grupy wysokiego ryzyka wg kryteriów NCI lub grupa standardowego ryzyka ze szczególnymi czynnikami ryzyka
- •Prawidłowe funkcje wątroby (parametry bilirubiny i transaminaz w normie)
- •Prawidłowe funkcje nerek (parametry funkcji nerek odpowiednie dla wieku)
- •Dla chłoniaków limfoblastycznych: stadium 3-4 lub stadium 1-2 u pacjentów powyżej 10 lat
- •Włączenie do badania INITIALL
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Novant Health Presbyterian Hemby Children's Hospital
Charlotte, United States
Saint Francis Children's Hospital
Tulsa, United States
St. Jude Children's Research Hospital
Memphis, United States
Trial contact
Seth E. Karol, MD, MSCI
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.